肝细胞癌早期诊断血清标志物研究进展

摘要/Abstract

摘要： 肝细胞癌（hepatocellular carcinoma,HCC）是源于肝脏细胞的恶性肿瘤,其有着恶性程度高,早期诊断困难,临床预后差的特点。近年来,越来越多的研究发现血清甲胎蛋白（alpha-fetoprotein,AFP）对于肝细胞癌诊断敏感性降低,早期诊断效能较差,因此,对于新型肝细胞癌血清肿瘤标志物的研究成为热点。例如甲胎蛋白异质体、热休克蛋白90、高尔基体蛋白73等的出现可能有效提高肝细胞癌的早期诊断率。本文就近年来对于肝细胞癌早期诊断血清标志物研究进展做一综述。

关键词: 肝细胞癌, 甲胎蛋白, 甲胎蛋白异质体, 热休克蛋白90, 高尔基体蛋白73

Abstract: Hepatocellular carcinoma is a malignant tumor originating from liver cells, which is characterized by high degree of malignancy, difficulty in early diagnosis, and poor clinical prognosis. In recent years, more and more studies have found that the sensitivity of serum alpha-fetoprotein for the diagnosis of hepatocellular carcinoma is reduced, and the early diagnostic efficacy is poor. Therefore, the study of new serum tumor markers for hepatocellular carcinoma has become a hot spot. For example, the presence of alpha-fetoprotein heteroplasmy, heat shock protein 90, and Golgi protein 73 may effectively improve the early diagnosis rate of hepatocellular carcinoma. This article reviews the research progress of serum markers for early diagnosis of hepatocellular carcinoma in recent years.

Key words: Hepatocellular carcinoma, Alpha-fetoprotein, fetoprotein L3, Heat-shock protein 90, Golgi protein 73

付佐君, 刘贵生. 肝细胞癌早期诊断血清标志物研究进展[J]. 肝癌电子杂志, 2021, 8(3): 51-54.

Fu Zuojun, Liu Guisheng. Research progress of serum markers for early diagnosis of hepatocellular carcinoma[J]. Electronic Journal of Liver Tumor, 2021, 8(3): 51-54.

参考文献

[1] TREVISANI FRANCO, GARUTI FRANCESCA, NERI ANDREA, et al.Alpha-fetoprotein for Diagnosis, Prognosis, and Transplant Selection[J].Semin Liver Dis, 2019, 39(2): 163-177.
[2] GALLE PETER R, FOERSTER FRIEDRICH, KUDO MASATOSHI, et al.Biology and significance of alpha-fetoprotein in hepatocellular Carcinoma[J].Liver Int, 2019, 39(12): 2214-2229.
[3] WORLAND T, HARRISON B, DELMENICO L, DOWLING D.Hepatocellular Carcinoma Screening Utilising Serum Alpha-Fetoprotein Measurement and Abdominal Ultrasound Is More Effective than Ultrasound Alone in Patients with Non-viral Cirrhosis[J]. J Gastrointest Cancer, 2018, 49(4): 476-480.
[4] TSUCHIYA N, SAWADA Y, ENDO I, et al.Biomarkers for the early diagnosis of hepatocellular carcinoma[J]. World J Gastroenterol, 2015,21(37): 10573-10583.
[5] WANG X, ZHANG Y, YANG N, et al.Evaluation of the Combined Application of AFP, AFP-L3%, and DCP for Hepatocellular Carcinoma Diagnosis: A Meta-analysis[J]. Biomed Res Int, 2020,17(2020): 5087643.
[6] QI F, ZHOU A, YAN L, et al.The diagnostic value of PIVKA-II, AFP, AFP-L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma[J].J Clin Lab Anal, 2019, 34(5): e23158.
[7] YEN CW, KUO YH, WANG JH, et al.Did AFP-L3 save ultrasonography in community screening?[J]. Kaohsiung J Med Sci, 2018, 34(10): 583-587.
[8] STREICHER JM.The Role of Heat Shock Proteins in Regulating Receptor Signal Transduction[J]. Mol Pharmacol, 2019, 95(5): 468-474.
[9] SUN Y, ZANG Z, XU X, et al.Differential proteomics identification of HSP90 as potential serum biomarker in hepatocellular carcinoma by two-dimensional electrophoresis and mass spectrometry[J]. Int J Mol Sci, 2010, 11(4): 1423-1433.
[10] FU Y, XU X, HUANG D, et al.Plasma heat shock protein 90alpha as a biomarker for the diagnosis of liver cancer: an official, large-scale, and multicenter clinical trial[J]. EBioMedicine, 2017, 24: 56-63.
[11] LU F.Serological diagnosis of hepatocelllulat carcinoma: challenge and opportunities[J]. J Clin Hepatol , 2017, 33(7): 1262-1265.
[12] N ZEKRI AR, El KASSAS M, SALAM ESE. The possible role of Dickkopf-1, Golgi protein-73 and Midkine as predictors of hepatocarcinogenesis: a review and an Egyptian study[J]. Sci Rep, 2020, 10(1): 5156.
[13] WONG RJ, AHMED A, GISH RG.Elevated alpha-fetoprotein: differential diagnosis-hepatocellular carcinoma and other disorders[J]. Clin Liver Dis, 2015, 19(2): 309-323.
[14] DE J, SHEN Y, QIN J, et al.A Systematic Review of Des-γ-Carboxy Prothrombin for the Diagnosis of Primary Hepatocellular Carcinoma[J]. Medicine (Baltimore), 2016, 95(17): e3448.
[15] TSUKAMOTO M, NITTA H, IMIA K, et al.Clinical significance of half-lives of tumor markers α-fetoprotein and des-γ-carboxy prothrombin after hepatectomy for hepatocellular carcinoma[J]. Hepatol Res, 2018 ,48(3): E183-E193.
[16] SI YQ, WANG XQ, FAN G, et al. Value of AFP and PIVKA-II in diagnosis of HBV-related hepatocellular carcinoma and prediction of vascular invasion and tumor differentiation[J]. Infect Agent Cancer, 2020, 23; 15(1): 70.
[17] LIN ZZ, HSU C, JENG YM, et al.Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma[J]. Liver Int, 2019, 39(9): 1682-1691.
[18] TSUKAMOTO M, NITTA H, IMAI K, et al. Clinical significance of half-lives of tumor markers α- fetoprotein and des-γ-carboxy prothrombin after hepatectomy for hepatocellular carcinoma[J]. Hepatol Res, 2018, 48(3): E183‐E193.
[19] HARUYAMA Y, KATAOKA H.Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma[J]. World J Gastroenterol, 2016, 22(1): 275-83.
[20] HAN N, WANG W, LU D,et al.A novel, rapid, and sensitive homogeneous sandwich detection method of Glypican-3 as a serum marker for hepatocellular carcinoma[J]. Chem Commun (Camb), 2017 ,53(90): 12209-12212.
[21] VONGSUVANH R, VAN DER POORTEN D, ISELIT,et al. Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma[J]. PLoSOne, 2016, 24; 11(5): e0155800.
[22] LU Q, LI J, CAO H, et al. Comparison of diagnostic accuracy of Midkine and AFP for detecting hepatocellular carcinoma: a systematic review and meta-analysis[J]. Biosci Rep, 2020, 27; 40(3): 2019-2424.
[23] ZHU WW, GUO JJ, GUO L, et al. Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma[J]. Clin Cancer Res, 2013, 19(14): 3944‐3954.
[24] HUANG H, WENG H, SUN W, et al.Author Correction: Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation[J]. Nat Cell Biol, 2018, 20(9): 1098.
[25] LIU GM, ZENG HD, ZHANG CY, et al.Identification of METTL3 as an Adverse Prognostic Biomarker in Hepatocellular Carcinoma[J]. Dig Dis Sci, 2021, 66(4): 1110-1126.
[26] LI J, WANG J, LEI L, et al.The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced multi-detector computed tomography in detecting hepatocellular carcinoma: a meta-analysis of eight prospective studies[J]. Eur Radiol, 2019, 29(12): 6519-6528.
[27] YAN L, XU F, DAI C. Overexpression of COL24A1 in Hepatocellular Carcinoma Predicts Poor Prognosis: A Study Based on Multiple Databases, Clinical Samples and Cell Lines[J]. Onco Targets Ther, 2020, 2; 13: 2819-2832.
[28] TAN C, CAO J, CHEN L, et al.Noncoding RNAs Serve as Diagnosis and Prognosis Biomarkers for Hepatocellular Carcinoma[J]. Clin Chem, 2019, 65(7): 905-915.
[29] LEE YR, KIM G, TAKWY, et al. Circulating exosomal noncoding RNAs as prognostic biomarkers in human hepatocellular carcinoma[J]. Int J Cancer, 2019, 144(6): 1444-1452.
[30] TAN C, CAO J, CHEN L, et al.Noncoding RNAs Serve as Diagnosis and Prognosis Biomarkers for Hepatocellular Carcinoma[J]. Clin Chem, 2019, 65(7): 905-915.
[31] JUN L, YANG G, ZHISU L.The utility of serum exosomal microRNAs in hepatocellular carcinoma[J]. Biomed Pharmacother, 2019, 111: 1221-1227.
[32] HOAC B, NELEA V, JIANG W, et al.Mineralization-inhibiting effects of transglutaminase-crosslinked polymeric osteopontin[J]. Bone, 2017, 101: 37-48.
[33] LI J, CHEN X, DAI M, et a. Diagnostic accuracy of osteopontin plus alpha-fetoprotein in the hepatocellular carcinoma: A meta-analysis[J]. Clin Res Hepatol Gastroenterol, 2017,41(5): 543-553.
[34] GAO X, SHENG Y, YANG J, et al.Osteopontin alters DNA methylation through up-regulating DNMT1 and sensitizes CD133+/CD44+ cancer stem cells to 5 azacytidine in hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2018, 37(1): 179.
[35] HUAMAN J, NAIDOO M, ZANG X, et al.Fibronectin Regulation of Integrin B1 and SLUG in Circulating Tumor Cells[J]. Cells, 2019, 8(6): 618.
[36] GUO W, SUN YF, SHEN MN, et al.Circulating Tumor Cells with Stem-Like Phenotypes for Diagnosis, Prognosis, and Therapeutic Response Evaluation in Hepatocellular Carcinoma[J]. Clin Cancer Res, 2018, 24(9): 2203-2213.
[37] NG CKY, DI COSTANZO GG, TOSTI N, et al.Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study[J]. Ann Oncol, 2018, 29(5): 1286-1291.
[38] HUANG A, ZHANG X, ZHOU SL, et al.Detecting Circulating Tumor DNA in Hepatocellular Carcinoma Patients Using Droplet Digital PCR Is Feasible and Reflects Intratumoral Heterogeneity[J]. J Cancer, 2016,7(13): 1907-1914.
[39] YANG JD, LIU MC, KISIEL JB.Circulating Tumor DNA and Hepatocellular Carcinoma[J]. Semin Liver Dis, 2019, 39(4): 452-462.
[40] LUO Z, MAO X, CUI W.Circular RNA expression and circPTPRM promotes proliferation and migration in hepatocellular carcinoma[J]. Med Oncol, 2019, 36(10): 86.
[41] SUN ALLEY, WENG YALI.Research Progress of Circular RNA in Diagnosis and Prognosis of Hepatocellular Carcinoma[J]. World Clinical Drugs, 2020, 41(7): 540-545.
[42] LUO Z, MAO X, CUI W.Circular RNA expression and circPTPRM promotes proliferation and migration in hepatocellular carcinoma[J]. Med Oncol, 2019, 36(10): 86.
[43] YU J, XU QG, WANG ZG, et al.Circular RNA cSMARCA5 inhibits growth and metastasis in hepatocellular carcinoma[J]. J Hepatol, 2018,68(6): 1214-1227.
[44] 周剑,孙惠川,王建华,等. 中国原发性肝癌诊治指南(2017版)[J].肝癌,2018,7(3):235-260.
[45] SURVEILLANCE GROUP DIAGNOSIS GROUP; STAGING GROUP.Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan[J]. J Formos Med Assoc, 2018,117(5): 381-403.
[46] BENSON AB, D'ANGELICA MI, ABBOTT DE, et al. Guidelines Insights: Hepatobiliary Cancers, Version 2.2019[J]. J Natl Compr Canc Netw,2019, 17(4): 302-310.